Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohortPrismRA demonstrates a more efficient therapy selection protocol beyond current standardThree...
Study demonstrates Scipher Medicine’s ability to analyze patient data to identify novel treatments.Scipher will focus on pharma collaborations in autoimmune diseases. June 8, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with...
– Leverages large genomic database from Scipher’s testing business- Proven SpectraTM platform brings precision therapeutics to autoimmune diseases.- Program commercialized through pharma partnerships. MAY 4, 2021 – WALTHAM, MA – Scipher Medicine, a precision...
-aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization of precision medicine PrismTM portfolio of blood tests and data partnerships in autoimmune...
New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced...
First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021- WALTHAM, MA- Scipher Medicine, a precision immunology company matching patients with the most effective therapy, announced today they have partnered with...
